Helsinki, Finland

Elina Ikonen

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Orphazyme A/s. Active years: 2021.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Elina Ikonen: Innovator in Cholesterol Homeostasis

Introduction

Elina Ikonen is a prominent inventor based in Helsinki, Finland. She has made significant contributions to the field of biomedicine, particularly in the area of cholesterol homeostasis. Her innovative work focuses on the role of heat shock proteins in treating diseases associated with cholesterol dysregulation.

Latest Patents

Elina Ikonen holds a patent titled "Heat shock proteins and cholesterol homeostasis." This patent provides bioactive agents that increase the intracellular concentration and/or activity of one or more heat shock proteins, including Hsp70. The invention is aimed at treating diseases linked to the dysregulation of cholesterol homeostasis. She has 1 patent to her name.

Career Highlights

Elina is currently associated with Orphazyme A/S, a company dedicated to developing innovative therapies for rare diseases. Her work at Orphazyme has positioned her as a key player in the research and development of treatments that leverage the body's natural mechanisms to address health challenges.

Collaborations

Throughout her career, Elina has collaborated with notable colleagues, including Thomas Kirkegaard Jensen and Burcin Gungor. These partnerships have enhanced her research efforts and contributed to the advancement of her innovative projects.

Conclusion

Elina Ikonen's contributions to the field of cholesterol homeostasis and her innovative patent highlight her role as a leading inventor in biomedicine. Her work continues to inspire advancements in the treatment of diseases related to cholesterol dysregulation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…